FDA Issues Complete Response Letter to Plinabulin Application for Prevention of Chemotherapy-Induced Neutropenia

Article

A complete response letter has been issued to BeyondSpring Pharmaceuticals for plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

The FDA has issued a complete response letter to the makers of plinabulin regarding a new drug application for the agent in combination with granulocyte colony-stimulating factor (G-CSF) as a prophylactic treatment against chemotherapy-induced neutropenia (CIN), according to a press release from developer BeyondSpring.1

The letter indicates that after reviewing the application, the FDA has determined that the treatment cannot be approved in its current form. The FDA stated that the application, which included findings from a single registration phase 3 trial, did not demonstrate clear significant benefit that would have warranted an approval and that a second, well-controlled clinical trial will be necessary to produce the evidence needed to support the regimen in a CIN indication.

Notably, plinabulin is the first agent submitted to the FDA for approval that could potentially be used in the first week of treatment with chemotherapy prior to G-CSF in order to prevent the onset of CIN and improve patient outcomes.

“BeyondSpring strongly believes that plinabulin in combination with G-CSF has significant potential to raise the standard of care in CIN, a devastating [adverse] effect of chemotherapy,” said Lan Huang, PhD, co-founder, chief executive officer, and chairwoman at BeyondSpring, said in a press release. “The company plans to request a meeting with the FDA and remains committed to its goal of bringing plinabulin to cancer patients in need globally.”

Plinabulin and G-CSF received priority review from the FDA in June 2021 based on findings from the pivotal phase 3 PROTECTIVE-2 trial (NCT03294577), which compared plinabulin/pegfilgrastim versus pegfilgrastim alone.2 Data from the trial included 1200 patients. The primary end point of improved grade 4 neutropenia in cycle 1 was met, with a rate of 13.6% in the plinabulin arm and 31.5% in the control arm (P = .0015).

References

  1. BeyondSpring Pharmaceuticals receives complete response letter from the FDA for plinabulin new drug application for prevention of chemotherapy-induced neutropenia (CIN). News release. BeyondSpring Pharmaceuticals. December 1, 2021. Accessed December 1, 2021. https://bit.ly/3pflFWJ
  2. BeyondSpring announces U.S. FDA acceptance and priority review of new drug application for plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia (CIN). News release. BeyondSpring, Inc. June 1, 2021. Accessed December 1, 2021. https://bit.ly/3fCQuAQ

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.